Collection and analysis of biological samples from patients with multiple myeloma and related conditions
Official title: EMN Prospective Sample Collection Project
Run by European Myeloma Network B.V. · NCT06237803 · Data updated 2026-11-12
This study is collecting and storing blood samples from patients with multiple myeloma and similar conditions to help researchers learn more about these diseases and improve treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 6000 (estimated) |
| Sponsor | European Myeloma Network B.V. Research network |
| Locations | 41 sites (Melbourne and 40 other locations) |
| Status | Recruiting |
| Started | December 21, 2022 |
| Main results expected | December 2037 |
| Study ends | December 2037 |
| Registry record updated | December 3, 2025 |
| Trial ID | NCT06237803 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older diagnosed with MGUS, smoldering multiple myeloma, multiple myeloma, or plasma cell leukemia.
✕Probably not a fit
Patients who have previously received anti-myeloma therapy or have had serious adverse reactions to blood donation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a common international infrastructure for the prospective collection, storage, and analysis of biological samples from patients diagnosed with multiple myeloma, smoldering multiple myeloma, plasma cell leukemia, and related conditions. It will gather standard clinical variables at baseline and during treatment to facilitate future research. The study involves multiple centers across Europe and focuses on creating a comprehensive biobank for better understanding and treatment of these conditions.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of multiple myeloma and related conditions, potentially leading to improved treatment strategies.
How similar studies have gone: Other studies focusing on biobanking and observational data collection in hematological malignancies have shown success, indicating the potential for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects with MGUS, smouldering Multiple Myeloma (SMM) , MM (Multiple Myeloma) (+/- EMD), plasma cell leukemia (PCL) (+/- EMD) * Subjects are ≥ 18 years old. * Subjects have provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any project-specific activities or procedures. 1. Subjects do not have kind of condition that, in the opinion of the Investigators, may compromise the ability of the subjects to give written informed consent and 2. subjects are, in the investigator's opinion, willing and able to comply with the protocol requirements. Exclusion Criteria: * Previous treatment with anti-myeloma therapy (excluding one course of therapy in patients in which urgent therapy is deemed necessary according to physician's discretion, e.g. myeloma-related complications resistant to supportive care). * Subjects have had prior unforeseen (serious) adverse reactions to blood donation including, but not limited to fainting, angina, severe bruising, allergic reactions, or any other adverse events. * Any psychological, familial, sociological and geographical condition potentially hampering compliance with the protocol and follow-up schedule.
Where it's running
-
Alfred Hospital
Melbourne, Australia Recruiting -
KUK Linz
Linz, Austria Recruiting -
Medical University Vienna
Vienna, Austria Recruiting -
Department of Haematology UZ Leuven Gasthuisberg
Leuven, Belgium Recruiting -
Nemocnice Havířov
Havířov, Czechia Recruiting -
Nemocnice Nový Jičín
Nový Jičín, Czechia Recruiting
Show 35 more locations
-
Fakultní nemocnice
Olomouc, Czechia Recruiting -
Slezská nemocnice
Opava, Czechia Recruiting -
Fakutni nemocnice Ostrava
Ostrava, Czechia Recruiting -
Nemocnice Pelhrimov
Pelhřimov, Czechia Recruiting -
Všeobecná Fakultní nemocnice v Praz
Prague, Czechia Recruiting -
Regional General Hospital Alexandra Dept of Clinical Therapeutics
Athens, Greece Recruiting -
Theagenion Cancer Hospital
Thessaloniki, Greece Recruiting -
Beaumont Hospital, Dublin, Hematology Department
Galway, Ireland Recruiting -
A.O. 'SS. Antonio e Biagio'
Alessandria, Italy Recruiting -
AOU Ospedali Riuniti di Ancona
Ancona, Italy Recruiting -
Bari-A.O.U. Consorziale Policlinico - Medicina Interna
Bari, Italy Recruiting -
Policlinico S Orsola Malpighi
Bologna, Italy Recruiting -
A.O.Spedali Civili di Brescia
Brescia, Italy Recruiting -
A.S.U.R. Regione Marche
Civitanova Marche, Italy Recruiting -
A.O.U. Careggi
Florence, Italy Recruiting -
A.O.U. Policlinico S. Martino - Clinica Ematologica
Genova, Italy Recruiting -
A.O.U. Policlinico S. Martino - Ematologia
Genova, Italy Recruiting -
A.O. 'Cardinale G.Panico'
Lecce, Italy Recruiting -
A.O. di Rilievo Nazionale A. Cardarelli
Naples, Italy Recruiting -
A.O.U. Maggiore della Carità
Novara, Italy Recruiting -
Policlinico S. Matteo Fondazione IRCCS - Pavia
Pavia, Italy Recruiting -
A.O. San Camillo-Forlanini
Roma, Italy Recruiting -
Ospedale S. Eugenio
Roma, Italy Recruiting -
I.R.C.C.S. Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, Italy Recruiting -
A.O. S. Maria
Terni, Italy Recruiting -
A.O.U. Città della Salute e della Scienza di Torino - PO Molinette
Torino, Italy Recruiting -
Azienda Ospedaliera Universitaria di Udine
Udine, Italy Recruiting -
ULSS8 Berica Ospedale S.Bortolo
Vicenza, Italy Recruiting -
Chuc
Coimbra, Portugal Recruiting -
Fundação Champalimaud
Lisbon, Portugal Recruiting -
Chsj - Hosp. Sao Joao
Porto, Portugal Recruiting -
IPOP Porto
Porto, Portugal Recruiting -
Clinic of Hematology, University Clinical Center of Serbia
Belgrade, Serbia Recruiting -
Chuv
Lausanne, Switzerland Recruiting -
HOCH Health Ostschweiz Kantonsspital St.Gallen
Sankt Gallen, Switzerland Recruiting
Study contacts
- Study coordinator: Chiara Del Pietro
- Email: chiara.delpietro@emn.org
- Phone: +31 10702687065
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cohort of patients with plasma cell disorders at Peking University First Hospital
This study is looking at hospitalized patients with plasma cell disorders to see how their treatment and disease status affect their outcomes over time.
-
Registry for adults with plasma cell disorders
This study is creating a registry for adults with plasma cell disorders like multiple myeloma to track their health and care experiences over time while also collecting blood samples for future research.
-
How N-glycosylation of light chains affects AL amyloidosis diagnosis and treatment
This project will test whether a sugar modification called N-glycosylation on immunoglobulin light chains helps cause disease or changes how AL amyloidosis and related monoclonal gammopathies behave in adults.
-
Prolonged overnight fasting combined with a Mediterranean-style diet for people with multiple myeloma or precursor conditions
This program will test whether longer overnight fasting paired with a Mediterranean-style eating plan is doable for adults with MGUS, smoldering myeloma, or newly diagnosed multiple myeloma who are starting treatment.
-
Using Whole Body MRI to Improve Cancer Detection
This study is testing if Whole Body MRI can help find bone and soft tissue problems in people with different types of cancer, like lymphoma and advanced prostate and breast cancer.
-
Combining JNJ-79635322 with Daratumumab or Pomalidomide for Multiple Myeloma Treatment
This study is testing a new drug called JNJ-79635322 combined with either daratumumab or pomalidomide to see how safe and effective it is for people with multiple myeloma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.